Al Garfall
@algarfall.bsky.social
Hematologist/Oncologist at the University of Pennsylvania with clinical and research focus on multiple myeloma and related plasma cell disorders.
Explore this gift article from The New York Times. You can read it for free without a subscription. www.nytimes.com/2025/02/13/o...
Opinion | I Shudder to Imagine Kennedy Running Our Health Agencies. (Gift Article)
We have to go toe-to-toe with this administration and resist its attacks on public health.
www.nytimes.com
February 14, 2025 at 8:08 AM
Explore this gift article from The New York Times. You can read it for free without a subscription. www.nytimes.com/2025/02/13/o...
Important observations by our group @penncancer.bsky.social, led by Dr. Matthew Ho, on non-tuberculous mycobacterial infections in multiple myeloma patients on teclistamab: haematologica.org/article/view...
Early View
| Haematologica
haematologica.org
February 10, 2025 at 3:48 PM
Important observations by our group @penncancer.bsky.social, led by Dr. Matthew Ho, on non-tuberculous mycobacterial infections in multiple myeloma patients on teclistamab: haematologica.org/article/view...
It was wonderful to get together in-person with our multi-site team working on the LimiTec trial of limited-duration teclistamab therapy for rel/ref #myeloma at #ASH24! Thanks to Leukemia & Lymphoma Society for supporting our trial! clinicaltrials.gov/study/NCT059... @myelomateacher.bsky.social
December 9, 2024 at 12:33 AM
It was wonderful to get together in-person with our multi-site team working on the LimiTec trial of limited-duration teclistamab therapy for rel/ref #myeloma at #ASH24! Thanks to Leukemia & Lymphoma Society for supporting our trial! clinicaltrials.gov/study/NCT059... @myelomateacher.bsky.social
Reposted by Al Garfall
Not every day a leading US academic health system partners with @costplusdrugs.com, bypassing PBMs, to save drug costs for their patients
@pennmedicine.bsky.social + @mcuban.bsky.social
www.pennmedicine.org/news/news-re... a 1st-of-its-kind deal
@pennmedicine.bsky.social + @mcuban.bsky.social
www.pennmedicine.org/news/news-re... a 1st-of-its-kind deal
Penn Medicine partners with Mark Cuban’s Cost Plus Drugs
Penn Medicine has partnered with Mark Cuban's Cost Plus Drug Company through its innovative Cost Plus Marketplace in a strategic alliance that will allow Penn Medicine to secure the top 100 most frequ...
www.pennmedicine.org
December 7, 2024 at 8:32 PM
Not every day a leading US academic health system partners with @costplusdrugs.com, bypassing PBMs, to save drug costs for their patients
@pennmedicine.bsky.social + @mcuban.bsky.social
www.pennmedicine.org/news/news-re... a 1st-of-its-kind deal
@pennmedicine.bsky.social + @mcuban.bsky.social
www.pennmedicine.org/news/news-re... a 1st-of-its-kind deal
Reposted by Al Garfall
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
www.mountsinai.org
November 30, 2024 at 7:17 PM
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Reposted by Al Garfall
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 29, 2024 at 8:04 PM
Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Re-posting this starter pack on multiple myeloma, now updated with a few more accounts. Please share and let me know if I’m missing anyone!
go.bsky.app/REknptc
go.bsky.app/REknptc
November 25, 2024 at 3:28 AM
Re-posting this starter pack on multiple myeloma, now updated with a few more accounts. Please share and let me know if I’m missing anyone!
go.bsky.app/REknptc
go.bsky.app/REknptc
Reposted by Al Garfall
🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...
TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function
Modulation of exhausted CD8+ T cell differentiation by targeting TET2 improves therapeutic potential of CAR T cells in cancer.
www.science.org
November 19, 2024 at 12:45 PM
🚨NEW🧪: TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function - #CARTCell #immunotherapy #TCell #tcellrx #immunology www.science.org/doi/10.1126/...
Reposted by Al Garfall
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW
November 22, 2024 at 2:33 PM
If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW
Reposted by Al Garfall
#ASH24 Peripheral Residual Disease (PRD) by mass spect and MRD by NGF in NDMM (GEM2017FIT Trial)
-79.6% concordance
-integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...
-79.6% concordance
-integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...
November 21, 2024 at 10:40 PM
#ASH24 Peripheral Residual Disease (PRD) by mass spect and MRD by NGF in NDMM (GEM2017FIT Trial)
-79.6% concordance
-integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...
-79.6% concordance
-integration of PRD into routine clinical practice may be beneficial for all elderly pts #mmsm ash.confex.com/ash/2024/web...
Hi all, I created this starter pack of accounts related to multiple myeloma research and clinical care. Please let me know whom I'm missing, and I will update! go.bsky.app/REknptc
November 21, 2024 at 4:15 PM
Hi all, I created this starter pack of accounts related to multiple myeloma research and clinical care. Please let me know whom I'm missing, and I will update! go.bsky.app/REknptc